GlassScriptPhysician profile
Holly Franklin
NPI 1467090746
$4,525.20
in general payments reported to CMS, 2019-2025
30 companies · $532 in 2025
The $532 reported for 2025 was more than what 75% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $794 · 2022: $1,125 · 2023: $1,058 · 2024: $1,016 · 2025: $532.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,606.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,606.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,445.26 | 2021-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $450.74 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $324.63 | 2021-2024 | Verquvo |
| Atricure, INC. | $290.57 | 2023-2024 | |
| E.R. Squibb & Sons, L.L.C. | $235.16 | 2021-2025 | Camzyos, Eliquis |
| Pfizer INC. | $223.25 | 2022-2025 | |
| Amgen INC. | $175.75 | 2022-2024 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $148.79 | 2021-2024 | Jardiance |
| Boston Scientific Corporation | $146.92 | 2021-2023 | Watchman Access System |
| Janssen Pharmaceuticals, INC | $112.16 | 2021-2023 | Xarelto |
| Itamar Medical INC | $109.21 | 2022 | |
| Cvrx, INC. | $107.37 | 2023 | Barostim Neo System |
| Alnylam Pharmaceuticals INC. | $89.87 | 2022-2024 | Amvuttra |
| Actelion Pharmaceuticals US, INC. | $87.84 | 2022-2025 | Opsumit, Uptravi, Opsynvi |
| Kiniksa Pharmaceuticals International, Plc | $87.65 | 2024 | Arcalyst |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $72.23 | 2021-2024 | Wainua, Farxiga |
| Lexicon Pharmaceuticals, INC. | $68.64 | 2023-2024 | Inpefa |
| Kestra Medical Technology Services, INC. | $49.91 | 2022-2023 | Assure Wcd |
| Edwards Lifesciences Corporation | $47.69 | 2023-2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Cleerly, INC. | $37.10 | 2025 | Cleerly Ischemia, Cleerly Labs |
| Kiniksa Pharmaceuticals, LTD. | $35.46 | 2023 | Arcalyst |
| Novo Nordisk INC | $33.22 | 2024-2025 | Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $26.50 | 2022-2023 | |
| Cmp Pharma, INC. | $25.26 | 2023 | Norliqva, Tadliq, Carospir |
| Philips North America LLC | $19.63 | 2022 | |
| Inspire Medical Systems, INC. | $17.95 | 2024 | Inspire |
| Bridgebio Pharma, INC. | $15.61 | 2025 | Attruby |
| Lilly USA, LLC | $14.59 | 2025 | Zepbound, Mounjaro |
| Amarin Pharma, INC. | $13.29 | 2021 | |
| Medtronic, INC. | $12.95 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Holly Franklin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.